AMRX NASDAQ
Amneal Pharmaceuticals, Inc.
1W: +1.6%
1M: -3.1%
3M: -14.3%
YTD: -1.9%
1Y: +67.4%
3Y: +511.8%
5Y: +120.2%
$12.42
+0.00 (+0.00%)
Weekly Expected Move ±4.3%
$11
$11
$12
$12
$13
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (85)
Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term
3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX)
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
Amneal Pharmaceuticals beats top-line and bottom-line estimates; reaffirms FY26 outlook
Amneal Reports First Quarter 2026 Financial Results
Amneal Reports First Quarter 2026 Financial Results
Do Options Traders Know Something About Amneal Stock We Don't?
Amneal (AMRX) Q3 2025 Earnings Call Transcript
Amneal (AMRX) Q2 2025 Earnings Transcript
Amneal (AMRX) Q1 2026 Earnings Transcript
Earnings Scheduled For May 1, 2026
Here are the major earnings before the open Friday
Amneal Pharmaceuticals Q1 2026 Earnings Preview
Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High?
Amneal Pharmaceuticals (AMRX) is a Top-Ranked Momentum Stock: Should You Buy?
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?
Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?
Amneal 2026-2027 Upside From Biosimilars Scale
AMRX Valuation: What 1.69x Sales Means for Investors
AMRX Growth Drivers: Generics, Biosimilars, and Crexont
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results
Amneal anticipates deleveraging below 3x by 2028 as it outlines $4.3B-$4.5B 2030 revenue target following Kashiv deal
Amneal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
Why Is Amneal Pharmaceuticals Stock Gaining Today?
Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
Amneal rated Buy in new research coverage at UBS as growth pipeline expands
Strength Seen in Bioventus (BVS): Can Its 6.6% Jump Turn into More Strength?
AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook
Is AMRX Stock Undervalued? Sales Multiple, Target, Upside
Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing
Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
Amneal to Report First Quarter 2026 Results on May 1, 2026
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $14.20 Average Target Price from Analysts
Allspring Global Investments Holdings LLC Grows Stock Position in Amneal Pharmaceuticals, Inc. $AMRX
Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by SG Americas Securities LLC
Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Assenagon Asset Management S.A.
Most oversold mid-cap healthcare stocks on Wall Street amid Middle East disruptions
Algert Global LLC Cuts Stock Position in Amneal Pharmaceuticals, Inc. $AMRX
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $14.20 Average Price Target from Analysts
New Strong Buy Stocks for March 9th
Best Value Stocks to Buy for March 9th
Citigroup Inc. Purchases 101,166 Shares of Amneal Pharmaceuticals, Inc. $AMRX
Amneal to Participate in Upcoming Investor Conference
Amneal outlines 2026 guidance with 12% to 24% EPS growth target, signals acceleration in affordable medicines
Amneal Pharmaceuticals Non-GAAP EPS of $0.21 beats by $0.03, revenue of $814M beats by $6.68M
Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript
Amneal Pharmaceuticals (AMRX) Q4 Earnings Top Estimates
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
Here are the major earnings before the open Friday
Amneal Pharmaceuticals Q4 2025 Earnings Preview
Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?
Earnings week ahead: NVDA, CRM, HD, BIDU, LOW, DELL, SNOW, AMC, ZM, and more
Brokerages Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Target Price at $13.80
Is Amneal Pharmaceuticals (AMRX) a Great Value Stock Right Now?
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $13.80 Average PT from Brokerages
Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Grows By 28.4%
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson's Disease
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of “Moderate Buy” by Analysts
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of “Moderate Buy” from Analysts
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
Assenagon Asset Management S.A. Raises Holdings in Amneal Pharmaceuticals, Inc. $AMRX
Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson's Disease
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
Amneal to Participate in Upcoming Investor Conferences
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares?
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?
Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs